logo

Your gate­way

to finance

and inno­va­tion

in Cen­tral Europe

Gen­eral

Fifth Cen­tral Euro­pean Life Sci­ence Invest­ment Conference

Hotel Stary, Krakow, 2223 Octo­ber 2015


    • Early bird registration

until 4th Sep­tem­ber 2015

950 PLN + 23% VAT

or €290 + 23% VAT

    • Stan­dard registration

from 5th Sep­tem­ber 2015

1600 PLN + 23% VAT

or €450 + 23% VAT

    • Accom­pa­ny­ing persons

If you would like to bring a friend please be in contact.

If there is suf­fi­cient inter­est we will develop an interesting

agenda for accom­pa­ny­ing persons.

There will be a mod­est fee.


    • Extra din­ner guest

250zl + 23% VAT

70 + 23% VAT


By reg­is­ter­ing you acknowl­edge hav­ing read the dis­claimer and under­stood the can­cel­la­tion policy


Pay­ment by bank trans­fer in Euros to: PKO Bank Pol­ski in Krakow

94 1440 1127 0000 0000 1386 1129

Pay­ment by bank trans­fer in Pol­ish zloty to: PKO Bank Pol­ski in Krakow

68 1440 1127 0000 0000 1134 2701

Kod BIC (Swift): BPKOPLPW

Reg­is­ter

Reg­is­tra­tion closed

Agenda

This year’s theme:

“New invest­ment vehi­cles and oppor­tu­ni­ties – focus on Poland”

Agenda cor­rect on 18 Octo­ber 2015

21 Octo­ber 2015

18.00

Reg­is­tra­tion open

19.00

Pre-​conference Drinks Recep­tion at the Hotel Stary

22 Octo­ber 2015

MAIN CON­FER­ENCE STARTS

08.00 Reg­is­tra­tion Open

09.45

Wel­come
Leszek Grabar­czyk, The National Cen­tre for Research and Devel­op­ment; NCBR (Poland)

Roland Kozlowski, LSBC (Poland)

10.00 Ses­sion: Per­spec­tives on life sci­ence investment

Morn­ing Ses­sion Chair: Krzysztof Jakubczak, LSBC, Poland

10.00

Talk + Q&A: Patric Gresco, EIF, Luxemburg

Cur­rent trends in the Euro­pean ven­ture cap­i­tal indus­try and the role of the EIF

10.30

Talk: Olivier Mur­phy, Deloitte, Poland

The Pol­ish biotech sector

11.00 Cof­fee & Networking


11.45 Ses­sion: Private-​public part­ner­ship and seed­ing inno­va­tion: first fruits emerge

11.45

Talk: Bridge VC Leszek Grabar­czyk

The National Cen­tre for Research and Devel­op­ment; NCBR (Poland)

12.00

Talk: The role of the Pol­ish Agency for Enter­prise Devel­op­ment in fund­ing inno­va­tion.
Michal Banka, The Pol­ish Agency for Enter­prise Devel­op­ment (Poland)

12.15

Talk: An analy­sis of early stage research in Poland

Krzysztof Jakubczak, LSBC, Poland

12.45

Talk: Invest­ment oppor­tu­ni­ties emerg­ing from the Bridge VC program

Edyta Niem­czyk, LSBC, Poland


13.15 Net­work­ing lunch

14.15 Ses­sion: Agro bio – cur­rent trends and oppor­tu­ni­ties for investment

After­noon Session

After­noon Ses­sion Chair Bar­tosz Wal­ter, LSI, Poland

Talk: Gareth Davies, Agrotech Entre­pre­neur, UK

14.45

Panel dis­cus­sion: Cur­rent trends in the world of Agro – bio

Panel Mod­er­a­tor: Roland Kozlowski, LSBC, Poland

Jacek Brol, BASF, Poland

Gareth Davies, Agrotech Entre­pre­neur, UK

Joanna Zarzyn­ska, SGGW, Poland

Mar­tin Rand, Vital Fields, Estonia

Tomasz Kołoszczyk, ORANGE, Poland

15.30

TEA & Networking

16.15

Talk: Val­u­a­tion of life sci­ence projects – the real­i­ties and rela­tion­ship to deal structures

Claire Brown, Alder­ley Park Ven­tures, UK

16.45

Talk: IP the cor­ner­stone for a life sci­ence business

Nicola Baker-​Munton, Strat­a­gem, UK

17.15

Con­fer­ence close for the day

19.15

Net­work­ing drinks, Con­fer­ence Din­ner, Live Music: Restau­rant Pod Roza

23 Octo­ber 2015

7.45

Inno­va­tion is Great — Busi­ness Breakfast

Busi­ness Break­fast, UKTI

Mark Tre­herne, UKTI, UK

Mar­tin Oxley, UKTI, Poland

Ses­sion Starts 9.15 Invest­ments and exits

Ses­sion Chair Edyta Niem­czyk, LSBC, Poland

9.15

Talk: Invest­ments and exits some per­sonal experiences

Jonatan Gee, Spark Ven­tures, UK

9.45

Talk: Doing busi­ness in the U.S. from an FDA per­spec­tive: Approvals & Enforcement

Andrew Har­ri­son, RCA, US

10.15

Panel Dis­cus­sion:

Invest­ments and exits: can you plan ahead?

Panel Mod­er­a­tor: Mark Tre­herne, UKTI, UK

Sander van Deven­ter, For­bion, Netherlands

Adam Cudny, Life Sci­ence Invest­ments, Poland

Axel Polack, Joint Pol­ish Invest­ment Fund, Poland

Francesco De Ruber­tis, Index Ven­tures, Switzer­land /​US

11.00

Cof­fee and networking

11.45

Talk: Change Man­age­ment – adap­ta­tion to west­ern markets

Andrew Skowron­ski, A&C Asso­ciates, UK

12.15

Panel dis­cus­sion: how to man­age per­cep­tion of the Pol­ish Brand and attract invest­ment from, and do busi­ness with the west

Panel Mod­er­a­tor: Oliver Mur­phy, Deloitte, Poland

Felice van Wee­gen, LSP, Netherlands

Kinga Drechny, Jagiel­lon­ian Uni­ver­sity, Poland

Heiko Vis­ar­ius, Vis­ar­tis, Switzerland

Mar­iusz Jarze­bowski, Ven­ture IQ x demosEU­ROPA, Poland

Sergiusz Sawin, Inno­vatika, Poland

13.00

Sum­ming up & Con­fer­ence Close

Roland Kozlowski (LSBC)

13.3015.30

Round­table dis­cus­sion for Investors Inter­ested in Invest­ment in inno­va­tion in Poland Pri­vate Pub­lic Part­ner­ship oppor­tu­ni­ties over lunch.

Antic­i­pated Par­tic­i­pants: LSP, Adi­uvo, LSI, Wyw­ern, Index, JPI, For­bion and others.

Speak­ers

        • Nicola Baker-Munton
          Nicola Baker-​Munton
        • Michał Bańka
          Michał Bańka
        • Jacek Brol
          Jacek Brol
        • Claire Brown
          Claire Brown
        • Adam Cudny
          Adam Cudny
        • Gareth Davies
          Gareth Davies
        • Sander van Deventer
          Sander van Deventer
        • Kinga Drechny
          Kinga Drechny
        • Jonathan Gee
          Jonathan Gee
        • Leszek Grabarczyk
          Leszek Grabar­czyk
        • Patric Gresko
          Patric Gresko
        • Andrew Harrison
          Andrew Har­ri­son
        • Krzysztof Jakubczak
          Krzysztof Jakubczak
        • Mariusz Jarzebowski
          Mar­iusz Jarzebowski
        • Tomasz Koloszczyk
          Tomasz Koloszczyk
        • Roland Kozlowski
          Roland Kozlowski
        • Oliver Murphy
          Oliver Mur­phy
        • Edyta Niemczyk
          Edyta Niem­czyk
        • Martin Oxley
          Mar­tin Oxley
        • Axel Polack
          Axel Polack
        • Martin Rand
          Mar­tin Rand
        • Francesco De Rubertis
          Francesco De Rubertis
        • Sergiusz Sawin
          Sergiusz Sawin
        • Andrew Skowronski
          Andrew Skowron­ski
        • Mark Treherne
          Mark Tre­herne
        • Heiko Visarius
          Heiko Vis­ar­ius
        • Bartosz Walter
          Bar­tosz Walter
        • Felice van Weegen
          Felice van Weegen
        • Joanna Zarzynska
          Joanna Zarzyn­ska

Nikola Baker-Munton

Nikola Baker-​Munton

Nicola Baker-​Munton is the founder and Chief Exec­u­tive Offi­cer of Strat­a­gem Intel­lec­tual Prop­erty Man­age­ment Lim­ited. Nicola started her career in busi­ness qual­i­fy­ing as a UK Patent Agent and Euro­pean Patent Attor­ney at The Well­come Foun­da­tion Lim­ited, hav­ing gained a joint hon­ours degree in biol­ogy and bio­chem­istry. Dur­ing her nine years as an indus­trial prac­ti­tioner at Well­come, Nicola recog­nised the need for much greater assis­tance with com­mer­cial intel­lec­tual prop­erty man­age­ment in the pri­vate sec­tor, in par­tic­u­lar for SMEs and aca­d­e­mic insti­tu­tions help­ing them to pro­tect and com­mer­cialise their sci­ence. Work­ing in the pri­vate sec­tor from 1995, Nicola founded Strat­a­gem IPM in 1999, and has gained con­sid­er­able expe­ri­ence of actively and strate­gi­cally man­ag­ing intel­lec­tual prop­erty port­fo­lios from incep­tion through devel­op­ment to mar­ket, and from acad­e­mia through startup to stock mar­ket list­ing. The suc­cess of the holis­tic approach to strate­gic IP man­age­ment led to the cre­ation of Strat­a­gem Cor­po­rate Finance & Strat­egy Ltd in 2001 which helps with seed fund­ing, re-​financing and the finan­cial re-​structuring of com­pa­nies. Build­ing on her con­sid­er­able expe­ri­ence in nego­ti­a­tion, in 2007 Nicola qual­i­fied as an accred­ited medi­a­tor pro­vid­ing fur­ther skills for dis­pute res­o­lu­tion in the IP and gen­eral cor­po­rate arenas.


Michał Bańka

Michał Bańka

Michał Bańka worked at the Min­istry of Econ­omy to man­age and medi­ate imple­men­ta­tion of sev­eral EU funded pro­grams. Since 2006 his respon­si­bil­i­ties have included run­ning the finan­cial depart­ments of three Pro­grams: (1) Improv­ing the Com­pet­i­tive­ness of Enter­prises, (2) Inno­v­a­tive Econ­omy and (3) Infra­struc­ture and Envi­ron­ment. He has held the posi­tions of Deputy Direc­tor, and from 2012 Direc­tor of the Depart­ment of Busi­ness Envi­ron­ment Insti­tu­tion Sup­port of the Pol­ish Agency for Enter­prise Devel­op­ment. His respon­si­bil­i­ties include: (1) Pro­vid­ing sup­port for busi­ness incu­ba­tors in find­ing inno­v­a­tive ideas and cap­i­tal input for “Start-​ups”, (2) Sup­port of the ‘Busi­ness Angels’ Net­work, (3) Sup­port for Busi­ness Envi­ron­ment Insti­tu­tions, (4)

Orig­i­na­tor, Loan fund man­agers for micro and small enter­prises with the par­tic­i­pa­tion of busi­ness angel or ven­ture cap­i­tal fund.

Financ­ing of advi­sory ser­vices that are nec­es­sary to attract exter­nal investors. His busi­ness career is com­bined with an aca­d­e­mic role involv­ing teach­ing at the Fac­ulty of Polit­i­cal Sci­ence at War­saw Uni­ver­sity. He is the project man­ager and gen­eral exec­u­tive of R & D projects of the Min­istry of Sci­ence and Higher Edu­ca­tion and author and co-​author of sev­eral mono­graphs and sci­en­tific articles.


Jacek Brol

Jacek Brol

Mar­ket­ing Man­ager at BASF Pol­ska Sp. o.o.

Result dri­ven mar­ket­ing pro­fes­sional with diverse inter­na­tional back­ground. Has about 18 years of expe­ri­ence within Agri busi­ness in var­i­ous mar­ket­ing roles con­cen­trat­ing on mar­ket approach strate­gies, team and peo­ple devel­op­ment with a focus on cus­tomers. Proved his lead­er­ship skills by effec­tively dri­ving and imple­ment­ing com­plex multi-​functional team projects. He started his car­rier at BASF in sales, and after six years spent on close col­lab­o­ra­tion with farm(s) moved onto mar­ket­ing. He has gained inter­na­tional expe­ri­ence being respon­si­ble for prod­uct launches in Cen­tral Euro­pean coun­tries. Has broad expe­ri­ence in:

- Exper­tise in agchem industry

- Analy­sis of value chains, mar­ket trends and mar­ket forecast

- Port­fo­lio– und Prod­uct Life­cy­cle Management

- Lead­ing cross func­tional, mul­ti­cul­tural project teams

- Devel­op­ment of pric­ing strategies

- Strat­egy devel­op­ment and implementation

Jacek Brol grad­u­ated from Wro­claw Uni­ver­sity of Envi­ron­men­tal and Life Sci­ences with a degree in Agriculture.


Clarie Brown

Clarie Brown

Claire Brown, PhD, MBA. Claire Brown is cur­rently an Invest­ment Man­ager for a Life Sci­ence focused Seed fund based out of Man­ches­ter, UK. Prior to this she was a Project Direc­tor at Astrazeneca respon­si­ble for the deliv­ery of strate­gic cross ther­apy sci­en­tific ini­tia­tives, iden­ti­fy­ing & secur­ing inno­v­a­tive invest­ment oppor­tu­ni­ties for AZ-​Medimmune and in-​licensing & repo­si­tion­ing inter­nal assets.

She has over 15 years expe­ri­ence work­ing within the Bio­phar­ma­ceu­ti­cal indus­try man­ag­ing projects across a vari­ety of ther­apy areas and mul­ti­ple stages of devel­op­ment includ­ing life cycle man­age­ment. Prior to Astrazeneca Claire held a vari­ety of Sci­en­tific focused roles in the U.S. at UCB and Gen­zyme, gain­ing expe­ri­ence across a vari­ety of modal­i­ties (incl. cell ther­apy, recom­bi­nant pro­teins, and devices) and areas of research (inc. orphan diseases)

Edu­cated in Scot­land Claire first received her BSc (Hons) from the Uni­ver­sity of Glas­gow, sub­se­quently fol­lowed by a PhD and more recently an MBA.


Adam Cudny

Adam Cudny

Adam Cudny Pres­i­dent of the Board, CEO, Invest­ment Committee

Finan­cial expert with over 20 year-​experience. Com­pleted 3 inde­pen­dent finance fac­ul­ties: Mas­ters’ Degree in Econ­omy at PWS­BiA War­saw and two other finance-​related in Lon­don (CIMA and ACCA). Since 1996 he has been con­nected with inter­na­tional finance (6 years in PwC, 15 years in Trio Man­age­ment, Hexa Group), own­er­ship super­vi­sion (7 years in Rely­onart VC Fund) and fund-​raising for start-​ups in IT sec­tor and pro­fes­sional ser­vices. Board Mem­ber of >10 com­pa­nies, cre­ated >50 start-​ups, with total asset value under active man­age­ment of > PLN 50M, appraised and car­ried out ca. 30 trans­ac­tions in Poland and abroad val­ued >PLN 1B.


Gareth Davies

Gareth Davies

Gareth is an agrotech entre­pre­neur based in Cam­bridge, UK. His com­pany, Yagro, is an inter­net plat­form which allows farm­ers to bench­mark and pur­chase agri­cul­tural input prices (seeds, fer­til­izer, chem­i­cals). Yagro is cur­rently in its seed fund­ing round.

Before launch­ing Yagro, Gareth worked for the global agribusi­ness giant Syn­genta in Basel, Switzer­land. His roles included run­ning an incu­ba­tor for new busi­ness mod­els, launch­ing a new ven­ture cap­i­tal port­fo­lio focused on emerg­ing mar­kets, and devel­op­ing derivatives-​based risk man­age­ment prod­ucts for farm­ers. He held a Board appoint­ment in a port­fo­lio com­pany and spo­ken reg­u­larly at indus­try con­fer­ences on behalf of Syngenta.

Gareth began his career as a man­age­ment con­sul­tant in the Lon­don office of a bou­tique strat­egy firm, and has worked in West Africa with the peer-​to-​peer micro­fi­nance lend­ing plat­form, Kiva​.org.

He holds a First Class Hon­ours Mas­ters degree in Chem­istry from Oxford Uni­ver­sity, and an MBA from the Lon­don Busi­ness School.


Sander van Deventer

Sander van Deventer

Sander van Deven­ter is a founder and man­ag­ing part­ner of For­bion Cap­i­tal Part­ners. He serves as a non-​executive on the boards of Argos Ther­a­peu­tics, Inc., giCare Inc., Hookipa AG, uniQure NV and enGene, Inc. He also is a pro­fes­sor in Transla-​tional Gas­troen­terol­ogy at the Uni­ver­sity of Lei­den and an accom­plished sci­en­tist: He authored more 400 peer-​review sci­en­tific papers and super­vised more than 40 PhD stu­dents. Sander van Deven­ter — a cer­ti­fied internist and gas­troen­terol­o­gist — received his med­ical degree and doc­tor­ate (of phi­los­o­phy) from the Uni­ver­sity of Ams­ter­dam, after defend­ing a the­sis on the bio­log­i­cal activ­i­ties of bac­te­r­ial lipopolysac­cha­rides in humans. Fol­low­ing board cer­ti­fi­ca­tion in inter­nal med­i­cine and gas­troen­terol­ogy he worked as a sci­en­tist in the Lab­o­ra­tory for Med­ical Bio­chem­istry, Rock­e­feller Uni­ver­sity, New York. He was the first to adminis-​ter an anti — TNF mon­o­clonal anti­body (later reg­is­tered as Rem­i­cade®) to patients with Crohn’s dis­ease, the first to infuse apolipoproteinA1 in humans and had a crit­i­cal role in the devel­op­ment of other ther­a­peu­tic inter­ven­tions, tar­get­ing cytokines, cytokine recep­tors, T-​cells and sig­nal trans­duc­tion path­ways, using small mol­e­cules, anti­bod­ies, pep­tides, pro­teins and anti-​sense DNA tech­nolo­gies. He super­vised the devel­op­ment of Gly­bera, the first gene ther­apy prod­uct to be approved in Europe, and sev­eral other gene ther­apy prod­ucts. In 1995, he became direc­tor of the lab­o­ra­tory for Exper­i­men­tal Inter­nal Med­i­cine at the Aca­d­e­mic Med­ical Cen­ter in Ams­ter­dam, and con­tin­ued to work on ther­a­peu­tic sig­nal trans­duc­tion inhi­bi­tion, gene thera-​pies, and (genet­i­cally engi­neered) pro­bi­otics. From 2001 until 2004, he chaired the Depart­ment of Gas­troen­terol­ogy and Hepa-​tology at the Aca­d­e­mic Med­ical Cen­ter in Ams­ter­dam. In 1998 he co-​founded Ams­ter­dam Mol­e­c­u­lar Ther­a­peu­tics (AMT N.V.) cur­rently uniQure B.V., devel­op­ing AAV-​based gene ther­apy prod­ucts and now listed on Nas­daq, act­ing sub­se­quently as CSO, CMO and CEO.


Kinga Drechny

Kinga Drechny

Kinga has a Master’s degree in Admin­is­tra­tion with a spe­cial­iza­tion in Pub­lic Rela­tions from the Jagiel­lon­ian Uni­ver­sity in Krakow, Poland. Ear­lier in her career Kinga worked for the Regional Gov­ern­ment and man­aged both pro­mo­tion and imple­men­ta­tion of the region’s tourist agenda. More recently she worked as the Mar­ket­ing Direc­tor for Krakow Air­port where she was respon­si­ble for pro­mo­tion of the air­ports activ­i­ties and pres­ence region­ally and inter­na­tion­ally. Presently Kinga holds the post of Mar­ket­ing Direc­tor for the Jagiel­lon­ian Uni­ver­sity — Poland’s most pres­ti­gious edu­ca­tional insti­tu­tion — where she is respon­si­ble for syn­the­sis and imple­men­ta­tion of the University’s, com­mu­ni­ca­tion, mar­ket­ing and PR strategy.

Kinga also works with LSBC assist­ing with mar­ket­ing and busi­ness development.


Jonathan Gee

Jonathan Gee

Dr Jonathan Gee Invest­ment Direc­tor SPARK Ven­ture Man­age­ment Ltd and SPARK Impact Ltd

Dr Gee is respon­si­ble for SPARK Ven­ture Management’s health­care and life sci­ences invest­ment activ­i­ties. He holds an invest­ment man­age­ment cer­tifi­cate and has over fif­teen years expe­ri­ence work­ing with IP dri­ven, high growth tech­nol­ogy com­pa­nies as an investor and board mem­ber. He is co-​chairman of the Invest­ment Com­mit­tee of the North­West Fund for Bio­Med­ical, a regional devel­op­ment (JERE­MII) fund sup­ported by ERDF and EIB. His invest­ment focus cov­ers all health­care from drug dis­cov­ery to med­ical soft­ware, devices and diag­nos­tics. Invest­ments he is or was respon­si­ble for include Adap­ti­m­mune, a can­cer ther­apy com­pany which IPO’d in April 2015 with a mar­ket cap on NAS­DAQ of $820m, Nat­ural Motion, a mobile gam­ing com­pany acquired by Zynga Inc for over $500m in Feb­ru­ary 2014, Oxford Immunotec, TB diag­nos­tics com­pany which floated on NAS­DAQ in Novem­ber 2013, Vivacta Ltd, a point of care diag­nos­tics busi­ness sold to Novar­tis for $90m in Decem­ber 2012, and Gly­cArt Biotech­nol­ogy, acquired by Roche for over £100m in July 2005. As Chief Exec­u­tive of Impe­r­ial Col­lege Inno­va­tions from 1997 to 2001, he was respon­si­ble for spin­ning out over 30 new Uni­ver­sity start up com­pa­nies. He estab­lished the first tech­nol­ogy seed fund at Impe­r­ial Col­lege and ran this for its first two years. He gained his man­age­ment train­ing in Unilever, and has a back­ground in mar­ket­ing in the med­ical diag­nos­tics indus­try where he was Inter­na­tional Prod­uct Group Man­ager at Unilever’s suc­cess­ful OTC preg­nancy test­ing com­pany, Uni­path. He holds a D Phil in can­cer research from Oxford Uni­ver­sity, and was awarded BSc in Cel­lu­lar Pathol­ogy with first class hon­ours by Bris­tol University.


Leszek Grabarczyk

Leszek Grabar­czyk

Leszek Grabar­czyk, Deputy Direc­tor, National Cen­tre for Research and Devel­op­ment (NCBR)

Since 2011, Leszek Grabar­czyk has been Deputy Direc­tor of the National Cen­tre for Research and Devel­op­ment (NCBR) – a gov­ern­ment agency with an annual bud­get of PLN 5.5bn which sup­ports the R&D sec­tor in Poland. He is respon­si­ble for the devel­op­ment and imple­men­ta­tion of pro­grammes that pro­mote inno­va­tion and research com­mer­cial­i­sa­tion. In 2014, the NCBR has launched BRIdge – a fam­ily of pro­grammes that con­sti­tute Poland’s first ever sys­tem of financ­ing new tech­nolo­gies by the public-​private part­ner­ship while using pri­vate equity funds together with the world’s largest enti­ties of this type. Thanks to the activ­i­ties of the NCBR, Poland’s R&D expen­di­ture in 2012 achieved a record result of PLN14.4 bil­lion – almost 23% more than in the pre­vi­ous year.


Patric Gresko

Patric Gresko

Patric Gresko is Head of Unit in EIF’s Ven­ture Cap­i­tal team. EIF is the largest Euro­pean ven­ture cap­i­tal fund-​of-​funds with more than EUR 3bn under man­age­ment and a port­fo­lio of over 220 ven­ture cap­i­tal funds.

Patric leads a team that invests in early stage funds and man­ages a port­fo­lio of ven­ture cap­i­tal funds rep­re­sent­ing total com­mit­ments of more than EUR1bn in all major tech­nol­ogy sec­tors. With EIF’s Ven­ture Cap­i­tal team, he is fur­ther devel­op­ing EIF’s activ­ity by design­ing and imple­ment­ing new inno­v­a­tive equity prod­ucts, notably in the impact invest­ing and cor­po­rate ven­tur­ing spaces.

He started his career with Price­wa­ter­house­C­oop­ers in Lux­em­bourg as an audi­tor and con­sul­tant for the finan­cial sec­tor. He holds an MSc in Busi­ness Engi­neer­ing from HEC Man­age­ment School – Uni­ver­sity of Liège.


Andrew Harrison

Andrew Har­ri­son

Andrew Har­ri­son Chief Reg­u­la­tory Affairs Offi­cer & Gen­eral Coun­sel Andrew serves as both Chief Reg­u­la­tory Affairs Offi­cer and Gen­eral Coun­sel, bring­ing over 14 years of exten­sive expe­ri­ence in tech­ni­cal qual­ity assur­ance, com­pli­ance, reg­u­la­tory affairs and gov­ern­ment affairs/​public pol­icy. He taps into his legal train­ing to ana­lyze and address key sit­u­a­tions impact­ing FDA-​regulated com­pa­nies. Andrew is a wel­come resource to our clients in need of strong domain sup­port on reg­u­la­tory approvals or clear­ances, clin­i­cal tri­als, adver­tis­ing & pro­mo­tion, good man­u­fac­tur­ing prac­tices, post-​approval require­ments, recalls or mar­ket with­drawals, audits, inspec­tions, warn­ing let­ters and enforce­ment actions such as injunc­tions and con­sent decrees. He can be reached at a.harrison(at)rcainc.com.


Krzysztof Jakubczak

Krzysztof Jakubczak

Krzysztof Jakubczak is a grad­u­ate from the Insti­tute of Opto­elec­tron­ics of the Mil­i­tary Uni­ver­sity of Tech­nol­ogy, War­saw, Poland. He achieved his PhD in the tech­ni­cal sci­ences from the Czech Tech­ni­cal Uni­ver­sity in Prague. His tech­ni­cal back­ground is in mil­i­tary tech­nolo­gies, lasers, optics (clas­si­cal, X-​ray and EUV), infrared tech­nol­ogy, light mod­u­la­tion and detec­tion, sec­ondary sources for nano­lith­o­g­ra­phy, vac­uum sys­tems and spec­troscopy. Krzysztof is an expe­ri­enced R&D engi­neer. As Deputy Project Man­ager he worked on design of HiLASE laser research cen­ter and estab­lish­ment of coop­er­a­tion with the par­ties. He led the R&D team as a Research Pro­gram Leader work­ing on devel­op­ment of lasers for indus­trial appli­ca­tions. His com­mer­cial expe­ri­ence cov­ers pro­duc­tion engi­neer­ing and R&D projects in med­ical devices as well as new star­tups. In march 2014 he joined LSBC as the Oper­a­tions Direc­tor within Bridge Men­tor Project to com­mer­cial­ize Life Sci­ence inven­tions in Poland. He man­ages the team of com­mer­cial­iza­tion experts and assesses com­mer­cial poten­tial of med­ical devices and tech­ni­cal projects.


Mariusz Jarzebowski

Mar­iusz Jarzebowski

Entre­pre­neur who has worked in the high-​tech indus­try in the United States, Aus­tria and Ger­many. Before com­ing back to Europe, Mar­iusz worked in Sil­i­con Val­ley at NeXT and Apple run by Steve Jobs. In Poland he was involved in estab­lish­ing and run­ning new ven­tures. Mar­iusz worked at a ven­ture cap­i­tal firm where he con­tin­ued to be involved in new ven­ture devel­op­ment, and served on the Board of Direc­tors and the Advi­sory Board. Mar­iusz helped com­pa­nies find and enter new mar­kets. At Microsoft, as a spe­cial­ist in com­pet­i­tive strat­egy and new mar­kets, he helped orga­ni­za­tions cre­ate new sources of growth, and learn from start-​ups. Helps com­pa­nies form and launch new ven­tures. Founder and owner Ven­ture IQ, a tech­nol­ogy intel­li­gence firm and Tech­nol­ogy Pol­icy Advi­sor at demosEU­ROPA – Cen­tre for Euro­pean Strat­egy, a think-​tank based in War­saw. Holds MBA and MS degrees from the War­saw Uni­ver­sity of Tech­nol­ogy Busi­ness School in part­ner­ship with Lon­don Busi­ness School. For more, visit www​.mar​iusz​jarze​bowski​.com.


Tomasz Koloszczyk

Tomasz Koloszczyk

Tomasz Koloszczyk. Busi­ness Devel­oper and Expert at Orange Poland.

He received M. Sc. degree at War­saw Uni­ver­sity of Tech­nol­ogy Fac­ulty of Applied Physics and Math­e­mat­ics and Master’s Cer­tifi­cate in Project Man­age­ment the George Wash­ing­ton University.

Dur­ing his pro­fes­sional career he worked for tele­com oper­a­tors, includ­ing: PTC (T-​Mobile), Teleko­mu­nikacja Pol­ska and Orange.

He man­aged numer­ous R&D and oper­a­tional projects related with var­i­ous ICT domains: IoT/​M2M, Smart City, e-​Health, Telecom­mu­ni­ca­tion net­works and Ser­vice Plat­forms, TV and mul­ti­me­dia ser­vices. He also coor­di­nated research domains at TP R&D.

He was active in Euro­pean research ini­tia­tives (i.e. Wire­less World Ini­tia­tive) and projects (as WP Leader) as well as stan­dard­iza­tion bod­ies (ITU-​T).

Cur­rently he is Busi­ness Devel­oper respon­si­ble for the devel­op­ment of prod­ucts and ser­vices in the domains of IoT /​M2M, Telemed­i­cine /​e-​Health in Orange Poland.

He is also a long­time the Euro­pean Com­mis­sion Eval­u­a­tor and Reviewer (DG Connect).

He is an author of pub­li­ca­tions related with ICT tech­nolo­gies and ser­vices. He gave pre­sen­ta­tions at var­i­ous con­fer­ences (includ­ing ICT-​Mobile Sum­mit IST Mobile and Wire­less Com­mu­ni­ca­tions Sum­mit, National Sym­po­sium of Telecommunications).


Roland Kozlowski

Roland Kozlowski

Roland Kozlowski received a first class hon­ours degree from the Uni­ver­sity of Bath and a PhD from the Uni­ver­sity of Cam­bridge. He is a bio-​entrepreneur who has worked in the indus­try for over two decades. Roland has held a num­ber of oper­a­tional roles includ­ing Chief Exec­u­tive Offi­cer of Lec­tus Ther­a­peu­tics and Sense Pro­teomic Lim­ited two ven­ture backed com­pa­nies which he founded, built and sold. Dur­ing his career Roland has gained con­sid­er­able trans­ac­tional expe­ri­ence rang­ing from com­pany sale, pur­chase, financ­ing and in– and out-​licensing. In the past Roland ran a Research Groups at the Uni­ver­sity of Oxford and then Uni­ver­sity of Bris­tol where sub­se­quently he was a Vis­it­ing Indus­trial Pro­fes­sor. He has pub­lished and patented in the life sci­ence field. Roland has served on, or advised, the boards of a num­ber of Euro­pean com­pa­nies. He also served on the board of the Bio-​Industry Asso­ci­a­tion in the UK. Since 2011 he has been pres­i­dent and owner of Life Sci­ence Biznes Con­sult­ing (LSBC) a com­pany which spe­cial­izes in com­mer­cial­iz­ing tech­nol­ogy from emerg­ing economies in par­tic­u­lar Poland and build­ing busi­ness part­ner­ships between Poland and West­ern Europe. He advises a num­ber of gov­ern­ment agen­cies in Poland on life sci­ence invest­ment and com­mer­cial­i­sa­tion strat­egy and is a co-​founder and Ven­ture Part­ner in Life Sci­ence Inno­va­tions a spe­cial­ist VC fund based in Poland. He also sits on the invest­ment com­mit­tee of Alder­ley Park Ven­tures a UK life sci­ence VC fund.


Oliver Murphy

Oliver Mur­phy

Oliver Mur­phy Part­ner Trans­ac­tion Advi­sory Ser­vicesO­liver is a grad­u­ate of the Uni­ver­sity of Man­ches­ter in Eco­nom­ics and Gov­ern­ment. He speaks flu­ent Pol­ish. Oliver has a wide range of cor­po­rate finance, due dili­gence and restruc­tur­ing and inte­gra­tion expe­ri­ence within both the UK and Poland and spe­cialises in cross-​border trans­ac­tion sup­port engage­ments com­pris­ing large multi-​disciplinary, multi­na­tional teams.


Edyta Niemczyk

Edyta Niem­czyk

Edyta Niem­czyk grad­u­ated from Inter­col­le­giate Fac­ulty of Biotech­nol­ogy, Uni­ver­sity of Gdańsk and Med­ical Uni­ver­sity of Gdańsk. She received a PhD in mol­e­c­u­lar biol­ogy from Med­ical Uni­ver­sity of Gdańsk, super­vised by excel­lent sci­en­tist from Nagoya Med­ical Uni­ver­sity in Japan – Prof. Takashi Wak­abayashi, who was a famous spe­cial­ist in pathol­ogy of mitochondria.

In order to fol­low the career path­way she envis­aged, she applied for the Post­doc­toral Research Asso­ciate posi­tion at the Uni­ver­sity of Liv­er­pool in UK with the pos­i­tive out­come. Dur­ing the two-​year con­tract she was acquainted with Sin­gle Nucleotide Poly­mor­phism (SNP) geno­typ­ing using Illu­mina arrays for the pur­pose of Famil­iar Pan­cre­atic Can­cer inves­ti­ga­tion. The next step for her career was to par­tic­i­pate in the project that would con­sider SNPs analy­sis using the most advanced tech­nol­ogy and analy­sis tools. That oppor­tu­nity was given to her at the Uni­ver­sity of Birm­ing­ham, when she was appointed for the Post­doc­toral Fel­low posi­tion where she was pas­sion­ately ana­lyz­ing asso­ci­a­tion of the genetic loci with acute ante­rior uveitis onset.

Edyta is expe­ri­enced geneti­cist per­fectly join­ing the pas­sion for the sci­ence and its com­mer­cial­iza­tion. Her key respon­si­bil­i­ties at LSBC as the Junior Com­mer­cial­iza­tion Expert are to assess prop­erly the sci­en­tific and com­mer­cial strengths of ana­lyzed projects.


Martin Oxley

Mar­tin Oxley

Mar­tin Oxley is Coun­try Head of UK Trade and Invest­ment at the British Embassy in War­saw. Prior to that he was CEO of the BPCC which under his lead­er­ship grew to be the lead­ing inter­na­tional busi­ness net­work­ing orga­ni­za­tion in Poland. Over the course of the last 15 years he has held CEO and Board posi­tions in the mar­ket lead­ing global and regional phar­ma­ceu­ti­cal com­pa­nies in Cen­tral Europe. He retains a strong inter­est in health­care, life sci­ences and enter­prise. He serves on the advi­sory boards of a num­ber of youth enter­prise net­works. He is a rec­og­nized inter­na­tional expert and speaker on Poland.


Axel Polack

Axel_​Polack

Dr. Axel Polack is a Gen­eral Part­ner at the “Joint Pol­ish Invest­ment Fund” (www​.JPI​Fund​.com), a life sci­ence ori­ented early stage ven­ture cap­i­tal fund. Before JPIF Dr. Polack was from 2000 to 2014 a key mem­ber of the Life Sci­ence team at TVM Cap­i­tal, which raised more than 680m€ in ven­ture cap­i­tal and accom­plished 67 invest­ments, 18 IPOs (“ini­tial pub­lic offer­ings”) and 15 trade sales. Prior to his career in ven­ture cap­i­tal he was involved in busi­ness man­age­ment as Gen­eral Man­ager and basic bio­med­ical research as Deputy Chair­man of a large research insti­tute. He has a proven track record in ven­ture cap­i­tal and early stage com­pany building.

Dur­ing his time as board mem­ber and lead investor rep­re­sen­ta­tive Genetix Inc. devel­oped into high fly­ing blue­bird bio Inc. which attracted 101m$ through an Ini­tial Pub­lic Offer­ing (IPO) at NAS­DAQ in June 2013. Due to break through suc­cesses in gene ther­apy the com­pany reached today a Mar­ket Cap of more than 5b$.

As long term board mem­ber of Alzheimer’s Dis­ease spe­cial­ist Pro­bio­drug AG (PBD) was instru­men­tal for the prepa­ra­tion of its IPO on Euronext Ams­ter­dam in Octo­ber 2014. It rep­re­sents one of the rare and suc­cess­ful IPOs of Ger­man biotech in recent years.


Martin Rand

Mar­tin Rand

Mar­tin Rand is the CEO and co– Founder of Vital­Fields– a global Farm Man­age­ment sys­tem. Mar­tin has always been pas­sion­ate about the inter­sec­tion if agri­cul­ture and IT. In 2003 he headed the cre­ation of the first mobile inspect­ing sys­tem for farm com­pli­ance inspec­tors. Mar­tin has also worked in Skype as a Prod­uct man­ager cre­at­ing sim­plest and most effi­cient IP com­mu­ni­ca­tion soft­ware. Sim­plic­ity is now the dri­ving fac­tor behind Vital­Fields which is the sim­plest crop man­age­ment sys­tem in the world. Vital­Fields aims to become the largest agri­cul­tural con­sult­ing plat­form turn­ing data into valu­able insight.


Francesco De Rubertis

Francesco De Rubertis

Francesco is a Part­ner and co-​founder of the firm’s life sci­ences prac­tice. He joined Index in 1998 and has over­seen all of the life sci­ences invest­ment of the firm. Present and past Index port­fo­lio com­pa­nies include: Xo1 (sold to John­son & John­son), Gly­co­V­axyn (sold to GSK), Oncoethix (sold to Merck), Ver­sar­tis (Nas­daq: VSAR), Egalet (Nas­daq: EGLT), Gen­mab A/​S (Coph: GEN​.CO), Mol­e­c­u­lar Part­ners A/​G (Swx: MOLN), Min­erva Neu­ro­sciences (Nas­daq: NERV), Aege­rion Inc. (Nas­daq: AEGR), Addex Phar­ma­ceu­ti­cals SA (Swx: ADXN), Pan­Genet­ics B/​V (sold to Abbott Phar­ma­ceu­ti­cals), Micromet Inc. (sold to Amgen) and Biox­ell SpA (sold to Cosmo Phar­ma­ceu­ti­cals). Francesco has served on most of these boards.

Prior to join­ing Index, Francesco was involved in post-​doctoral research in genet­ics at the White­head Insti­tute, Mass­a­chu­setts Insti­tute of Tech­nol­ogy (MIT). He is also the author of sev­eral pub­li­ca­tions in inter­na­tional sci­en­tific jour­nals. Francesco has a BA in Genet­ics and Micro­bi­ol­ogy from the Uni­ver­sity of Pavia and a PhD in Mol­e­c­u­lar Biol­ogy from the Uni­ver­sity of Geneva. He is a CFA char­ter holder, and is a mem­ber of the Strate­gic Advi­sory Board of the Uni­ver­sity of Geneva.

Francesco was named by BioWorld as one of 28 „movers and shak­ers” pre­dicted to shape the biotech­nol­ogy indus­try over the next two decades.


Sergiusz Sawin

Sergiusz Sawin

Sergiusz Sawin is the co-​founder and Chief Inno­va­tion Archi­tect at Inno­vatika – con­sult­ing com­pany focused of prod­uct and busi­ness inno­va­tion. His is also a board mem­ber of Inno­vatika Group and Chief Oper­at­ing Offi­cer at D-​Raft S.A. His deep back­ground in inno­va­tion stems from his exten­sive expe­ri­ence work­ing for Kraft Foods Poland (KFP), where he held var­i­ous posi­tions in finance and mar­ket­ing and was pri­mar­ily focused on mar­ket­ing research, brand & prod­uct inno­va­tion strate­gies. Dur­ing his career at Kraft, he was involved in more than a dozen mar­ket inno­va­tion projects and gained exper­tise in dif­fer­ent research method­olo­gies. Sev­eral of his new prod­uct devel­op­ment projects resulted in the launch of inno­va­tions that became key prod­ucts in KFP con­fec­tionery port­fo­lio. He also ini­ti­ated and coor­di­nated inter­na­tional com­mu­ni­ties of prac­tice related to con­sumer pro­mo­tions and brand equity building.

Mr. Sawin has acted as an inno­va­tion con­sul­tant for numer­ous clients, includ­ing 3M, Pol­ish Tele­com, Citibank, Danone, Mepha, Akzo Nobel, Siemens, Mars and Heinz, advis­ing on the devel­op­ment of inno­va­tion strate­gies and inno­va­tion cam­paigns, the improve­ment of new prod­uct devel­op­ment processes, and the intro­duc­tion of break­through prod­ucts. He was involved in the devel­op­ment of many Innovatika’s prod­ucts and ser­vices includ­ing Inno­va­tion Spring­board, Prod­uct Thinkdom, Rev­enue Gen­er­a­tor and Inno­va­tion Work­out. Mr. Sawin is also an expe­ri­enced trainer and facil­i­ta­tor: he has run work­shop ses­sions in Europe, USA, Rus­sia and South-​East Asia for groups of as many as 300 peo­ple. Since 2006 he’s run more than 50 train­ings on inno­va­tion and busi­ness model gen­er­a­tion for cor­po­rate clients, SMEs and Start-​ups help­ing them in the process of defin­ing their future busi­ness mod­els includ­ing the Busi­ness Model Mas­ter­class pro­gram devel­oped by Inno­vatika in 2013.

Since late 2014 he’s been involved in the devel­op­ment of new busi­ness entity – D-​Raft cor­po­rate accel­er­a­tor that inte­grates cor­po­ra­tions and startups.

Sergiusz Sawin grad­u­ated from the War­saw School of Eco­nom­ics. He holds two master’s degrees in Inter­na­tional Rela­tions and Man­age­ment & Mar­ket­ing (with hon­ors). He’s cur­rently work­ing on his PhD on Inno­v­a­tive Busi­ness Models.


Andrew Skowronski

Andrew Skowron­ski

Andy Skowron­ski the author of The Road to Trans­for­ma­tion was for­tu­nate to work for one com­pany who embraced Trans­for­ma­tional Think­ing and change.

The Road to Trans­for­ma­tion” is a Lead­er­ship and Change Man­age­ment pro­gram inspired by Andy’s time at Pep­siCo and Yum! Brands. Its aim is to set organ­i­sa­tions and indi­vid­u­als on a path of achiev­ing break­through think­ing and in turn break­through results.

Andy, is an expert with over 25 years indus­try expe­ri­ence with organ­i­sa­tions such as Pep­sico, Yum Brands and has worked advis­ing numer­ous pri­vate equity com­pa­nies around the world. An inter­na­tion­al­ist who has spent 18 years of his career work­ing abroad, in USA, Poland, the Mid­dle East and in the Far East and has exten­sive knowl­edge and con­nec­tions in these are­nas. Andy is an expe­ri­enced Strate­gist and Lead­er­ship coach, and has been train­ing senior exec­u­tives for the past 17 years.


Mark Treherne

Mark Tre­herne

Mark has been actively involved in the bio­phar­ma­ceu­ti­cal indus­try for 25 years and was a co-​founder and Chief Exec­u­tive of Cam­bridge Drug Dis­cov­ery Lim­ited, lead­ing the Company’s acqui­si­tion by Bio­Fo­cus plc, where he then became a Com­mer­cial Direc­tor, dri­ving sig­nif­i­cant growth of its prof­itable ser­vices busi­ness. Mark has now served on the Boards of 13 pri­vate and pub­lic bio­phar­ma­ceu­ti­cal com­pa­nies and is cur­rently on the Boards of Cycloflu­idic, Domain Ther­a­peu­tics, Pop­u­la­tion Genet­ics Tech­nolo­gies and Senexis. Dr Tre­herne has now helped raise more than £140 mil­lion for var­i­ous bio­phar­ma­ceu­ti­cal busi­nesses over the last decade. Mark was also for­merly Chair­man of ERBI Lim­ited, which is a not-​for-​profit organ­i­sa­tion that rep­re­sents the biotech­nol­ogy com­pa­nies based around Cam­bridge in the East of Eng­land. Mark ini­tially trained as a neu­ro­sci­en­tist and elec­tro­phys­i­ol­o­gist at Cam­bridge Uni­ver­sity. Mark joined the Life Sci­ence Invest­ment Organ­i­sa­tion as Chief Exec­u­tive, fol­low­ing its for­ma­tion by UK Trade and Investment.


Heiko Visarius

Heiko Vis­ar­ius

Dr. Heiko Vis­ar­ius is an exec­u­tive with inter­na­tional expe­ri­ence in the health care sec­tor, espe­cially in the area of med­ical device tech­nol­ogy. A Ph.D. in engi­neer­ing obtained in the USA and a Swiss/​US MBA degree com­bined with his pro­fes­sional expe­ri­ence allow him to relate to a broad spec­trum of busi­ness areas, such as sales, mar­ket­ing, R&D, finance, sup­ply chain and gen­eral man­age­ment. Dr. Heiko Vis­ar­ius served as CEO of a suc­cess­ful start-​up com­pany with an asso­ci­ated exit. Since then, he held var­i­ous lead­er­ship posi­tions with global play­ers of the med­ical device indus­try. He had P/​L respon­si­bil­ity in Europe for a 3-​digit mil­lion USD rev­enue vol­ume in a direct oper­a­tion. Since 2012, he is owner of VIS­AR­TIS Health­care GmbH. In addi­tion, Dr. Vis­ar­ius is board mem­ber of sev­eral Medtech com­pa­nies as well as an inter­na­tional busi­ness school and serves on var­i­ous expert boards, includ­ing Horizon2020 (Euro­pean Com­mu­nity). He and his fam­ily are located in Switzerland.


Felice van Weegen

Felice van Weegen

Felice van Wee­gen joined LSP in 2015. Felice’s respon­si­bil­ity within LSP is to sup­port both pri­vate and pub­lic invest­ment fran­chises in all stages of the invest­ment process. Prior to join­ing LSP, Felice was a con­sul­tant at McK­in­sey & Com­pany where she worked on projects in the Nether­lands, UK, Ger­many, Italy and Nige­ria and where she focused on the health­care and tech­nol­ogy sec­tors. Before she became a con­sul­tant, she was a neu­ro­sci­en­tist and sta­tis­ti­cal geneti­cist, work­ing with the pres­ti­gious com­plex traits genet­ics group at the Broad Insti­tute and Har­vard Med­ical School in Cam­bridge, USA where she mod­eled com­plex dis­ease genet­ics using large sequenc­ing datasets. Prior to that, she worked with the depart­ment of Bio­log­i­cal Psy­chol­ogy at the VU uni­ver­sity in Ams­ter­dam to pre­dict her­i­tabil­ity of sev­eral com­plex dis­or­ders using twin data and where she authored sev­eral sci­en­tific arti­cles. Felice has a strong sci­en­tific back­ground, includ­ing a Bachelor’s degree in Bio­log­i­cal psy­chol­ogy and a Master’s degree in Neu­ro­science from the VU uni­ver­sity in Ams­ter­dam. She also grad­u­ated with an MBA degree from Colum­bia Busi­ness School, New York USA.


Bartosz Walter

Bar­tosz Walter

Bar­tosz Wal­ter, PhD. Chief Oper­a­tion Offi­cer in Life Sci­ence Inno­va­tion Fund (Poland), involved in over 100 projects in last 5 years, investor, for­mer coor­di­na­tor of national pro­gram ‘Design the Future Poland’. For 10 years he worked as a sci­en­tist: Regens­burg Uni­ver­sity (PhD), Max Planck Insti­tute (Post-​doc), Pol­ish Acad­emy of Sci­ences (Assis­tant Pro­fes­sor) and Uni­ver­sity of Cal­i­for­nia Berke­ley (Exec­u­tive Edu­ca­tion). Alum­nus of TOP500 inno­va­tors (Poland). Awards: Schol­ar­ship of Min­istry of Sci­ence and Sport (Poland), Deutscher Akademis­cher Aus­tausch­di­enst (Ger­many), Tramp Schol­ar­ship (Germany).


Joanna Magdalena Zarzynska

Joanna Mag­dalena Zarzynska

Joanna Mag­dalena Zarzyńska – VMD, PhD. Grad­u­ate of the Fac­ulty of Vet­eri­nary Med­i­cine of the Uni­ver­sity of Warmia and Mazury in Olsz­tyn and Doc­toral Stud­ies at the Fac­ulty of Vet­eri­nary Med­i­cine, WULS-​SGGW in War­saw (her doc­toral dis­ser­ta­tion was awarded by the pres­ti­gious Prime Min­is­ter Prize). She has obtained a degree in „Man­age­ment of R & D projects” (post­grad­u­ate stud­ies, WSB School of Bank­ing in Gdansk). Since 2006 she works as an assis­tant pro­fes­sor in the Depart­ment of Food Hygiene and Pub­lic Health Pro­tec­tion (FVM, WULS-​SGGW). She is involved in projects related to dairy pro­duc­tion and food safety. Since 2011, she serves in expert board of the National Sci­ence Cen­tre. Joanna had par­tic­i­pated in numer­ous train­ing courses in the field of research man­age­ment of food pro­duc­tion sector.

The author or co-​author of sev­eral sci­en­tific pub­li­ca­tions and over 500 pop­u­lar pub­li­ca­tions, includ­ing 17 books. Since 2014 Edi­tor in Chief of ZooBiznes magazine.

Media

  • lsbc_konferencja_2015
  • lsbc_konferencja_2015_newsletter_czerwiec_wybrana
  • lsbc_konferencja_2015_newsletter_maj
  • lsbc_konferencja_2015_newsletter_sierpien
  • lsbc_konferencja_2015_newsletter_sierpien_inne

Atten­dees

Organ­i­sa­tions that have attended in the past:

Abcam

Aca­dia

Activ­iomics Ltd

Adamed

Amgen

Amrop

Appo­site Capital

Aquar­ius Fund

Assign Clin­i­cal Group

Babra­ham Bio­science Technologies

Ban­ner Group

Biotech Con­sult­ing

Biovec­tis

BLIRT

Boehringer Ingel­heim Pharma GmbH & Co KG

BTM Mazowsze

Bur­rill & Company

CIT­TRU

Crescendo Bio­log­ics Ltd

Deloitte

demosEU­ROPA

Dutch Biore­fin­ery Cluster

eFab­rica

EJ Palmer Consulting

Enter­prise Investors

Epither­a­peuitcs

EQT Part­ners

Euro­pean Commission

Euro­pean Invest­ment Fund

For­bion

FutureSyn­the­sis

Gideon Richter

Hep­endo Sp. z o. o.

Hep­tares Therapeutics

Hori­zon Discovery

Hun­gar­ian Biotech Asso­ci­a­tion (HU)

Impe­r­ial Innovations

Index Ven­tures

Nencki Insti­tute of Exper­i­men­tal Biology

Novozymes

Insty­tut Chemii Bioor­gan­icznej PAN

Insty­tut Farmaceutyczny

IOCB TTO

Jadara Pharma Ltd

Jagiel­lon­ian Uni­ver­sity, JCET

Jagiel­lońskie Cen­trum Innowacji

Lon­don Genet­ics International

MCI

Med­ical Research Coun­cil Tech­nol­ogy Group (MRCT)

Med­ical­go­rith­mics S.A.

Med­Im­mune Ltd

Medi­vir AB

Medtronic

Merck

National Cap­i­tal Fund

NBGI Ven­tures

Nickel Devel­op­ment

Orenore Sp. z o.o.

Osborne Clarke

Pol­ish Stock Exchange

Pol­pharma

ProPharma Part­ners Ltd

Pro­teon

Prox­im­a­gen

Pure Bio­log­ics s.c.

Royal Asso­ci­a­tion of Dutch Paper and Board Industries

RTC Inno­va­tion Ltd

QIA­GEN

Quin­tiles

Sage Health­care

Selvita S.A.

Sem­ple Fraser LLP

Seroba-​Kernel (UK/​IR)

Sitra

Sofinnova

South Mora­vian Inno­va­tion Centre

Takeda Research Investment

Tay­lor Wessing

The John Paul II Hospital

The National Cen­tre for Research & Development

The Pol­ish Agency for Enter­prise Development

TVM

UK Trade and Investment

Med­ical Uni­ver­sity Lodz

USP Life Sciences

Wro­claw Research Cen­tre EIT+

Dis­claimer

CAN­CEL­LA­TION POL­ICY & DISCLAIMER

Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. allows a change of reg­is­trant at no extra cost if the orig­i­nal reg­is­trant is unable to attend.

In the event of can­cel­la­tion of the Con­fer­ence by the orga­niz­ers all fees paid by del­e­gates will be returned in full although Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. is not respon­si­ble for any other finan­cial losses such as travel and hotel costs.

In the event that a del­e­gate or accom­pa­ny­ing per­son can­cels atten­dance at the con­fer­ence Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. will return 60% of the reg­is­tra­tion fee if atten­dance is can­celled before Fri­day 18 Sep­tem­ber 2015. There­after there will be no return of fees.

Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. is not liable in any way for any injuries, sick­ness or acci­dent or any costs incurred as a con­se­quence of such an event or any other losses to which a del­e­gate or accom­pa­ny­ing per­son may be sub­jected to whist trav­el­ling to or from Poland or whilst attend­ing the con­fer­ence in Krakow or any of the social events organized.

The speak­ers listed have all con­firmed their atten­dance and have agreed to post their pho­tographs on this web­site. How­ever Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. informs del­e­gates and speak­ers that that the final agenda could change for rea­sons beyond its con­trol. Life Sci­ence Biznes Con­sult­ing LSBC Sp. z o. o. reserves the right to make changes to the agenda and is not respon­si­ble for any finan­cial losses or costs incurred by par­tic­i­pants or del­e­gates in asso­ci­a­tion with their par­tic­i­pa­tion at this conference.

Spon­sors

main patron

NCBR
innovative-economy
eu

spon­sors

bioscience selvitalogo
RCA Deloitte

part­ners

parp UK Trade
Jagiellonian University in Krakow Jagiellonian Center of Innovation
Krajowy Punkt Kontaktowy

media part­ner

Berlin Partner Bio Partner
iitolse European Biotechnology
Pharm Rep Polska biotechnologia

Hotels

rec­om­mended hotels

Andel's Hotel Hotel Unicus Hotel Maltański
Hotel Amadeus Hotel Polski Hotel Wit Stwosz
Hotel Stary

LSBC has obtained pref­er­en­tial rates at these hotels which rep­re­sent a 10 to 25% dis­count on their stan­dard tar­iff. Please book as nor­mal quot­ing “LSBC con­fer­ence”. For more infor­ma­tion regard­ing detailed prices please con­tact: conference[at]lsbc.pl